ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
FDA Okays Practice-Changing Treatment For Liver Cancer
Executive Summary
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
You may also be interested in...
ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
Roche's Tecentriq Disappoints In Ovarian Cancer Study
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Need a specific report? 1000+ reports available Buy Reports